IP Library › Granted Patent US 9,808,420
Granted Patent B2
US 9,808,420 · App. 14/978,879 · Granted Nov 7, 2017

Drug delivery devices for delivery of ocular therapeutic agents

Inventors: Casey Kopczynski (Chapel Hill, NC); Cheng-Wen Lin (Durham, NC); Chris Sutay (Raleigh, NC)
Assignee: Novaer Holdings, INC.
A61K9/0051A61F9/0017A61K31/00A61K31/215A61K47/32A61K47/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,808,420
App. No.
14/978,879
Granted
Nov 7, 2017
Kind
B2
Abstract

Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.

Claims (17)

1. A device, comprising:

a composition in the form of a matrix of an active agent and a non-water soluble polymer, wherein the active agent comprises a latanoprost free acid salt, and wherein the non-water soluble polymer comprises ethylene vinyl acetate,

a first polymer portion;

a second polymer portion fused to the first polymer portion, the second polymer portion including a recess configured to support the composition; and

a third polymer portion fused to the second polymer portion;

wherein the total diameter of the device ranges from 3-5 mm, and

wherein the device is configured to:

(a) conform to a curvature of the eye,

(b) yield an elution rate of 0.00025-0.0075 micrograms/hr of the active agent, and

(c) release 70% to 90% of the active agent over a period of at least 30 days.

2. The device of claim 1 , wherein the first polymer portion, the second polymer portion, and the third polymer portion is selected from the group of: ethylene vinyl acetate with a vinyl acetate content from 10% to 50% by weight (EVA-10-50) and ethylene vinyl alcohol with a vinyl alcohol content from 40% to 80% by weight (EVOH40-80).

3. The device of claim 1 , wherein the first polymer portion, the second polymer portion, and the third polymer portion are manufactured from the same polymer.

4. The device of claim 1 , wherein the first polymer portion, the second polymer portion, and the third polymer portion are manufactured from a non-water soluble polymer.

5. The device of claim 4 , wherein the non-water soluble polymer is ethylene vinyl acetate having a vinyl acetate content of from 9% to 50% by weight.

6. The device of claim 5 , wherein the ethylene vinyl acetate content in the first polymer portion, the second polymer portion, and the third polymer portion are the same.

7. The device of claim 5 , wherein the ethylene vinyl acetate content in the first polymer portion, the second polymer portion, and the third polymer portion are different.

8. The device of claim 1 , wherein the non-water soluble polymer of the composition is ethylene vinyl acetate having a vinyl acetate content of from 9% to 50% by weight.

Continuity (2)
Division 13642042
Related Publication 20160106667A1 · Apr 21, 2016